Advisers to the U.S. Food and Drug Administration on Thursday voted to recommend approval of bluebird bio’s treatment for a rare neurological disorder, bringing it closer to becoming the third gene therapy to be available in the United States.
A patent cliff is looming once again for the biopharma industry, putting some $236 billion in pharmaceutical sales at risk between now and 2030. For context, the top 10 biopharmas in 2021 generated total global sales of $512 billion. In the next eight years, more than 190 drugs will go off-patent for these companies. Of those, 69 are blockbuster drugs.
An oral drug combination by Swiss pharmaceuticals company Novartis (NOVN.S) showed promise in treating a subgroup of patients suffering from a common childhood brain cancer in a trial.
Novartis is resuming business in Ukraine after reviewing how safe it was to operate in the country that Russia invaded in February, the Swiss drugmaker said.
The long weekend saw three established drugs developed by Bristol Myers Squibb, Novartis, and Roche score new approvals from the U.S. Food and Drug Administration.